Clusterin drives myeloid bias in aged hematopoietic stem cells by regulating mitochondrial function
Ninghe Sun1,2,3, Chun-Hsin Lin1,2,3, Michelle Y Li1,2,3
1Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
Insights
Aging impairs hematopoietic stem cells (HSCs). Clusterin (Clu) drives myeloid bias by affecting mitochondria. Depleting Clu rejuvenates HSC function and improves immunity.
Area of Science:
- Hematology
- Immunology
- Aging Research
- Molecular Biology
Background:
- Aged hematopoietic stem cells (HSCs) show reduced self-renewal and skewed myeloid differentiation, impacting hematopoiesis and immunity.
- The molecular mechanisms behind impaired aged HSC function are not fully understood.
Purpose of the Study:
- To identify molecular regulators of impaired aged HSC function.
- To elucidate the mechanism by which clusterin (Clu) drives myeloid-biased differentiation in aged HSCs.
Main Methods:
- Conducted an in vivo CRISPR-Cas9 screen to identify genes regulating HSC differentiation.
- Utilized molecular assays to investigate the interaction of Clu with Mfn2 and its effects on mitochondrial function and signaling pathways.
- Performed transplantation studies using Clu-depleted aged HSCs.
Main Results:
- Clusterin (Clu) was identified as a key driver of myeloid-biased differentiation in aged HSCs.
- Clu upregulation in aged HSCs promotes mitochondrial hyperfusion via Mfn2 interaction.
- Ablation of Clu reversed myeloid bias by attenuating oxidative phosphorylation and improving mitophagy through the OXPHOS-p38-Cebpb axis.
Conclusions:
- Clusterin (Clu) is a critical regulator of aging-associated myeloid bias in HSCs.
- The Mfn2-OXPHOS-p38-Cebpb axis mediates Clu's effect on myeloid differentiation.
- Targeting Clu offers a potential strategy for rejuvenating aged hematopoietic and immune systems.
Abstract:
Aged hematopoietic stem cells (HSCs) exhibit diminished self-renewal and myeloid-biased differentiation with a decline in hematopoiesis and adaptive immune function. However, the molecular regulation of this impaired function remains largely unknown. Here, through an in vivo CRISPR-Cas9-based screen, we uncovered clusterin (Clu) as a driver of biased differentiation. Clu is upregulated in aged HSCs, and its knockout diminishes biased differentiation. Clu promotes mitochondrial hyperfusion by interacting with Mfn2 in aged HSCs, and its ablation attenuates oxidative phosphorylation, improves mitophagy, and reverses myeloid-biased differentiation via the OXPHOS-p38-Cebpb axis. Transplantation of Clu-depleted aged HSCs into middle-aged mice results in balanced hematopoiesis and improved physical functions. Together, our data identify Clu as a critical regulator of aging-associated myeloid bias and reveal an Mfn2-OXPHOS-p38-Cebpb axis as the mechanism underlying how Clu upregulation in aged HSCs leads to myeloid-biased differentiation, providing a target for rejuvenation of aged hematopoietic and immune systems.
Related Concept Videos
Mitochondria
Regulation of Hematopoietic Stem Cells
Multipotency of Hematopoietic Stem Cells
Differentiation of Common Myeloid Progenitor Cells
Lineage Commitment
Regulation of Nuclear Protein Sorting


